Oculis Holding AG closed at $7.50 on Nov 12, down 1.45%, 77.0% below its 52-week closing high. Volume of 299.1K shares was 0.90× its 20-day average (close to normal).
Split-adjusted performance: +4.6% over one month, -75.2% over six months, -61.3% over one year.
Short interest was 1.6M shares at the Oct 30 settlement, down 11.3% from the prior report (3.6% of float, 5.6 days to cover).
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.
What is OCS's market cap?
$417.87M, based on the Nov 12 close of $7.50.
Does Oculis Holding AG pay a dividend?
No regular cash dividend has been paid in the last year.
How much of OCS is sold short?
1.6M shares, 3.6% of float, as of Oct 30, 2026.
About Oculis Holding AG
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company has locations in five countries: Switzerland, Iceland, France, U.S. and Hong Kong.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
